This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Montagnani Marelli, M. Articles by Limonta, P. Search for Related Content PubMed PubMed Citation Articles by Montagnani Marelli, M. Articles by Limonta, P.

Luteinizing Hormone-Releasing Hormone Agonists Interfere with the Mitogenic Activity of the Insulin-Like Growth Factor System in Androgen-Independent Prostate Cancer Cells¹

Center for Endocrinological Oncology, Department of Endocrinology, University of Milan, Milan, Italy

Address all correspondence and requests for reprints to: Dr. Patrizia Limonta, Department of Endocrinology, Center for Endocrinological Oncology, Via Balzaretti 9, 20133 Milan, Italy. E-mail: limonta{at}imiucca.csi.unimi.it

We have previously shown that LHRH agonists exert a direct and specific inhibitory action on the proliferation of the androgen-independent DU 145 prostate cancer cell line; however, the cellular mechanisms mediating this antiproliferative action are not well defined. It is well known that the insulin-like growth factor (IGF) system plays a crucial role in the local regulation of the growth of androgen-independent prostate cancer. The present experiments were performed to evaluate whether LHRH agonists might exert their antimitogenic effect by interfering with the activity of the locally expressed IGF system. To this purpose, the effects of the LHRH agonist Zoladex (LHRH-A) on 1) the mitogenic action of IGF-I, 2) the tyrosine phosphorylation of type 1 IGF-I receptor (IGF-IR), 3) the concentration of IGF-IR, and 4) the secretion of IGF-binding protein-3 were studied. The results obtained show that in DU 145 cells, LHRH-A 1) counteracts the mitogenic action of IGF-I in a dose-dependent manner, 2) prevents the IGF-I-induced tyrosine phosphorylation of the IGF-IR, 3) reduces the concentration of IGF-IR without affecting its K_d value, and 4) does not affect the secretion of IGF-binding protein-3 in the conditioned medium from these cells.

These data suggest that LHRH agonists may inhibit the proliferation of human androgen-independent prostate tumor cells by interfering with some of the cellular mechanisms mediating the stimulatory action of the IGF system.

This article has been cited by other articles:

				M. Kawada, H. Inoue, T. Masuda, and D. Ikeda Insulin-like Growth Factor I Secreted from Prostate Stromal Cells Mediates Tumor-Stromal Cell Interactions of Prostate Cancer. Cancer Res., April 15, 2006; 66(8): 4419 - 4425. [Abstract] [Full Text] [PDF]

				J. A. Wagmiller, J. J. Griggs, A. W. Dick, and D. M. Sahasrabudhe Individualized Strategy for Dosing Luteinizing Hormone-Releasing Hormone Agonists for Androgen-Independent Prostate Cancer: Identification of Outcomes and Costs J. Oncol. Pract, March 1, 2006; 2(2): 57 - 66. [Abstract] [Full Text] [PDF]

				K. Maiti, D. Y. Oh, J. S. Moon, S. Acharjee, J. H. Li, D. G. Bai, H.-S. Park, K. Lee, Y. C. Lee, N. C. Jung, et al. Differential Effects of Gonadotropin-Releasing Hormone (GnRH)-I and GnRH-II on Prostate Cancer Cell Signaling and Death J. Clin. Endocrinol. Metab., July 1, 2005; 90(7): 4287 - 4298. [Abstract] [Full Text] [PDF]

				C. K. Cheng and P. C. K. Leung Molecular Biology of Gonadotropin-Releasing Hormone (GnRH)-I, GnRH-II, and Their Receptors in Humans Endocr. Rev., April 1, 2005; 26(2): 283 - 306. [Abstract] [Full Text] [PDF]

				A. Rose, P. Froment, V. Perrot, M. J. Quon, D. LeRoith, and J. Dupont The Luteinizing Hormone-releasing Hormone Inhibits the Anti-apoptotic Activity of Insulin-like Growth Factor-1 in Pituitary {alpha}T3 Cells by Protein Kinase C{alpha}-mediated Negative Regulation of Akt J. Biol. Chem., December 10, 2004; 279(50): 52500 - 52516. [Abstract] [Full Text] [PDF]

				R. M. Moretti, M. Montagnani Marelli, J. C. Van Groeninghen, and P. Limonta Locally Expressed LHRH Receptors Mediate the Oncostatic and Antimetastatic Activity of LHRH Agonists on Melanoma Cells J. Clin. Endocrinol. Metab., August 1, 2002; 87(8): 3791 - 3797. [Abstract] [Full Text] [PDF]

				N. Auersperg, A. S. T. Wong, K.-C. Choi, S. K. Kang, and P. C. K. Leung Ovarian Surface Epithelium: Biology, Endocrinology, and Pathology Endocr. Rev., April 1, 2001; 22(2): 255 - 288. [Abstract] [Full Text]

				C. Gründker, K. Schulz, A. R. Günthert, and G. Emons Luteinizing Hormone-Releasing Hormone Induces Nuclear Factor {kappa}B-Activation and Inhibits Apoptosis in Ovarian Cancer Cells J. Clin. Endocrinol. Metab., October 1, 2000; 85(10): 3815 - 3820. [Abstract] [Full Text]

				S. K. Kang, K.-C. Choi, K. W. Cheng, P. S. Nathwani, N. Auersperg, and P. C. K. Leung Role of Gonadotropin-Releasing Hormone as an Autocrine Growth Factor in Human Ovarian Surface Epithelium Endocrinology, January 1, 2000; 141(1): 72 - 80. [Abstract] [Full Text] [PDF]

				P. Limonta, R. M. Moretti, M. M. Marelli, D. Dondi, M. Parenti, and M. Motta The Luteinizing Hormone-Releasing Hormone Receptor in Human Prostate Cancer Cells: Messenger Ribonucleic Acid Expression, Molecular Size, and Signal Transduction Pathway Endocrinology, November 1, 1999; 140(11): 5250 - 5256. [Abstract] [Full Text]